- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01683760
Pharmacokinetic Study of Fluconazole in Premature Infants
November 17, 2014 updated by: Han-Suk Kim, Seoul National University Hospital
The purpose of this study is to investigate the pharmacokinetics of fluconazole which is used as prophylaxis of invasive fungal infection in premature infants.
Study Overview
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul National University Children's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 4 weeks (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- very low birth weight infant (birth weight < 1,500 g) who were admitted to the NICU before day 3 of life
- Informed consent from the parents
Exclusion Criteria:
- Major congenital anomaly
- Expired within 72 hours of life
- Liver failure (AST or ALT levels with three times the upper limit of the range of normal values or higher)
- Proven congenital or intrauterine fungal infection
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Population PK
|
Prophylactic fluconazole administration in VLBW infants
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
drug level of fluconazole
Time Frame: 30min later, 10-12hr later, at routine lab with interval of 1week
|
four times drug level after 3th dose
|
30min later, 10-12hr later, at routine lab with interval of 1week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Han-Suk Kim, MD, PhD, Seoul National University Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2012
Primary Completion (Actual)
October 1, 2014
Study Completion (Actual)
October 1, 2014
Study Registration Dates
First Submitted
September 9, 2012
First Submitted That Met QC Criteria
September 9, 2012
First Posted (Estimate)
September 12, 2012
Study Record Updates
Last Update Posted (Estimate)
November 19, 2014
Last Update Submitted That Met QC Criteria
November 17, 2014
Last Verified
November 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Body Weight
- Birth Weight
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Fluconazole
Other Study ID Numbers
- FLU_PK
- 12172_231 (Other Grant/Funding Number: Korea Food and Drug Administration)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Very Low Birth Weight Infant
-
RESnTEC, Institute of ResearchCompleted
-
Princess Amalia Children's ClinicCompleted
-
Children's Hospital of Fudan UniversityCompleted
-
The Hospital for Sick ChildrenActive, not recruitingVery Low Birth Weight InfantCanada
-
Baylor College of MedicineCompletedInfant, Very Low Birth WeightUnited States
-
Wyss Institute at Harvard UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
The Hospital for Sick ChildrenUniversity of Toronto; Sinai Health SystemCompletedInfant, Very Low Birth WeightCanada
-
Children's Hospital of Fudan UniversityCompleted
-
Children's Hospital of Fudan UniversityNot yet recruitingVery Low Birth Weight InfantChina
-
Baylor College of MedicineCompletedInfant, Very Low Birth WeightUnited States
Clinical Trials on Fluconazole
-
Tanta UniversityCompletedEfficacy | Treatment | Safety | Fungal Keratitis | Fluconazole | Intrastromal InjectionEgypt
-
Academisch Medisch Centrum - Universiteit van Amsterdam...ZonMw: The Netherlands Organisation for Health Research and DevelopmentNot yet recruitingGut Microbiome | Healthy Adult Male | Antifungal TherapyNetherlands
-
Université de SherbrookeDalhousie UniversityRecruiting
-
Sunshine Lake Pharma Co., Ltd.Not yet recruiting
-
Urooj FatimaRecruitingDermatophytosis | Tinea CorporisPakistan
-
Makerere UniversityGilead Sciences; University of MinnesotaRecruitingCryptococcal MeningitisUganda
-
University of ManitobaManitoba Medical Service Foundation; Research ManitobaActive, not recruiting
-
Boehringer IngelheimCompleted
-
Eli Lilly and CompanyCompleted
-
PfizerCompleted